GeoVax to Present During China Showcase at Biotech Showcase 2018

Part of Larger Corporate Partnering Effort During the J.P. Morgan 36^th Annual Healthcare Conference

ATLANTA, GA, Jan. 02, 2018 --  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will deliver a presentation at the China Showcase during the Biotech Showcase 2018 conference. Dr. Guirakhoo’s presentation will be made at 2:00 p.m. on January 7, 2018 at the Parc 55 hotel in San Francisco, California.

The China Showcase is an event for companies and investors interested in cross-border investment and strategic partnering opportunities. Dr. Guirakhoo’s presentation will focus on the broad utility and impressive dataset being developed for GeoVax’s MVA-VLP vaccine platform, and he will provide an overview of the Company’s vaccine development programs in the areas of HIV, Zika, Lassa fever, malaria, hepatitis B immunotherapy, and immuno-oncology. Following the presentation, senior management of GeoVax will be available for one-on-one meetings with investment professionals and business development representatives from the life sciences industry.

Robert McNally, PhD, GeoVax’s President & CEO, commented, “While our presentation and attendance at the China Showcase is primarily focused on strategic opportunities with Chinese investors and biopharmaceutical companies, this is part of our larger effort during multiple events in San Francisco connected to the J.P. Morgan Annual Healthcare Conference on January 8-11, 2018. We continue to build a strong pipeline of preventive vaccines and immuno-therapeutics addressing multiple unmet medical needs in infectious diseases and cancer.  We look forward to connecting with many potential collaborators, partners and investors to communicate the value of our technology and the rationale for investing in the advancement of our vaccines to human clinical trials.”

Interested parties may schedule meetings with GeoVax through the conference websites for the Biotech Showcase (https://ebdgroup.knect365.com/biotech-showcase/), the Redefining Early Stage Investments (RESI) Conference (http://www.resiconference.com/), or through the partnering system hosted by the Biotechnology Innovation Organization (http://convention.bio.org/partner/). Meetings may also be scheduled by contacting Company management directly.

About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company’s HIV vaccine for the clade B epidemic in the Americas, Australia, Japan and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network (HVTN). Preclinical programs are focused on preventive vaccines for Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and effectively stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.

Robert T. McNally, Ph.D.
GeoVax Labs, Inc.
[email protected]
678-384-7220